New Average Target Price set up on Teva Pharma is US$75.14
Published By : 29 Jul 2015 | Published By : QYRESEARCH
The target price on the shares of Teva Pharma is raised from US$75.00 to US$85.00. Analysts at RBC Capital set the new target on the company, as per a report issue on July 29, 2015. The company have an ‘outperform’ rating on its stock, at present. The target price set by RBC Capital indicates a potential increase of 19.03% from the current price of the company.
Various other stock analysts have also shared their views on the pharmaceutical company. Morgan Stanley reiterated the ‘overweight’ rating, it previously gave this firm. Whereas, Sanford C. Bernstein upgraded their rating to a ‘buy’ in a market study published on Tuesday, July 28, 2015.
Another stock advising firm, Piper Jaffray reiterated a previously given ‘neutral’ rating and set a price target at US$75.00. Previously it has set a price target of US$57.00 on the company’s share. Canaccord Genuity set a price target of US$79.00 and restated the previous ‘hold’ rating on shares of Teva Pharma.
On the other hand, Citigroup Inc. raised its target on the pharma company’s shares from US$70 to US$86 and gave the firm a ‘buy’ rating. One stock analyst at Citigroup has given it a sell rating, whereas five other market experts have rated it with a ‘hold’ rating. However, 22 analysts have given the stock a ‘buy’ rating. Eventually, Teva Pharmaceuticals has a consensus ‘Buy’ rating and an average price target set at US$75.14, at present.
On Wednesday, July 29, 2015, the stocks of Teva Pharma opened at 71.41. The firm possesses a market cap of US$60.56 billion and a Price to Earnings ratio of 22.25. The firm’s stock has an average moving price of 50 days of US$61.87 and an average moving price of 200 days of US$60.59.